Business
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patientsFirst clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and comme
About this update from Olema Pharmaceuticals, Inc.
[{"type":"image","alt":"Olema Oncology","displaySize":"","headline":null,"caption":"Olema Oncology","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8WMDEniZEx5HC3l8.Api5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122","width":300,"height":86},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8WMDEniZEx5HC3l8.Api5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/b0eb35a98097b94ad61fdfb6ead09122","width":300,"height":86}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"First clinical data from OP-3136 Phase 1 study to be presented at ASCO ","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":286,"olType":false},{"type":"text","content":"SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2026.","length":367,"tagName":"p"},{"type":"text","content":"“We continued to meaningfully advance our pipeline of novel therapies focused on transforming the metastatic breast cancer treatment paradigm during the first quarter, with top-line data from our Phase 3 OPERA-01 trial of palazestrant as a monotherapy expected this fall and initial Phase 1 clinical data for OP-3136 being presented at ASCO later this month,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “We continued patient enrollment in OPERA-02, our Phase 3 trial of palazestrant in combination with ribociclib in the frontline metastatic setting, while advancing our ongoing Phase 1/2 combi...